
Community discussion centers on Ensysce's acquisition of Cy Biopharma and up to $77M financing, with bulls expecting a rally toward the $1 Nasdaq compliance level and Phase 3 interim data, while bears warn of dilution, a possible reverse split, and disappointment over the post-news selloff.